Reuters Health Information (2004-09-27): Drug-releasing beads lower complications of chemotherapy in small trial
Drug & Device Development
Drug-releasing beads lower complications of chemotherapy in small trial
Last Updated: 2004-09-27 13:18:38 -0400 (Reuters Health)
LONDON (Agence de Presse Medicale for Reuters Health) -
UK medical device company Biocompatibles on Saturday reported
preliminary results showing its drug-releasing beads can target liver
tumours without causing as many complications as standard chemotherapy.
Trial data on 15 liver cancer patients showed that drug-eluting
beads significantly reduced the body's overall exposure to chemotherapy
compared with established drug delivery techniques, the company said in
"The bead is loaded with high concentrations of doxorubicin but
little has been released into the circulation and the complications
have been correspondingly low," said trial investigator Ronnie Poon,
associate professor at the Centre for the Study of Liver Disease,
University of Hong Kong.
The study, presented at the Cardiovascular and Interventional
Radiological Society of Europe's meeting in Barcelona, also looked at
tumour responses in a small group of patients who had an MRI scan after
The findings were consistent with the study's goal of improving on
the 35% tumour response rate observed with the standard embolisation
technique, the company said.
Biocompatibles chief executive Crispin Simon told APM any therapy
that enables patients to tolerate higher doses of chemotherapy has
enormous medical and commercial potential. The bead might also be
developed for colorectal cancer.
The company said the trials were continuing and more data would be
released over the next 15 months. The bead was CE Marked earlier this
year and has been made available for physician evaluation in Europe and
certain other countries.